SCHOTT Pharma delivers strong second quarter of fiscal year 2025 Q2 2025 revenues up 8% yoy to EUR 252m; increase of 10% yoy at constant currencies Q2 2025 EBITDA margin of 28.6% as reported and 28.2% at constant currencies Share of strong-margin high-value solutions (HVS) at 56% in Q2 2025 SCHOTT Pharma reaffirms FY 2025 guidance SCHOTT Pharma [ … ]

 SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poonawalla TPG, a leading global alternative asset management firm will acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India (SII)  SII will retain a minority stake in the company, with SCHOTT Pharma  [ … ]

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe April 10, 2025, Jagodina, Serbia After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia Production capacity to meet European mar [ … ]

SCHOTT Pharma records good start into fiscal year and confirms full year outlook Q1 2025 revenues reached EUR 230m; decrease of 1% yoy as reported or increase of 4% at constant currencies Q1 2025 EBITDA margin of 25.1% as reported or 26.3% at constant currencies Share of strong-margin high-value solutions (HVS) further increased to 55% Busines [ … ]

SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items SCHOTT Pharma held its Annual General Meeting virtually on February 4, 2025 All items on the agenda were approved by shareholders Dr. Wolfram Carius has been appointed to SCHOTT Pharma’s Supervisory Board, replacing Dr. Wolfgang Wienand   SCHOTT Pharma,  [ … ]